Clinical Trial

Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial compares the effect of rifaximin to no intervention for the treatment of IgA monoclonal gammopathy of undetermined significance (MGUS). Rifaximin is a type of antibiotic that is only used in cancer chemotherapy (antineoplastic antibiotic). It works by damaging the cell's DNA and may kill cancer cells or precancerous cells like those found with MGUS. Giving rifaximin may kill more precancerous cells in patients with IgA MGUS.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-10-01; most recent amendment 2026-04-16.
Status change: Not Yet Recruiting → Recruiting 2025-11-19
Trial Details
NCT Number NCT07209371
Lead Sponsor Fred Hutchinson Cancer Center
Collaborators: Rising Tide Foundation
Conditions IgA Monoclonal Gammopathy of Undetermined Significance
Enrollment 50 participants
Start Date 2026-01-22
Primary Completion 2028-05-01 (estimated)
Study Completion 2028-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-20